Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
about
Emerging roles of PDGF-D in EMT progression during tumorigenesisMice Lacking Platelet-Derived Growth Factor D Display a Mild Vascular PhenotypeCircadian Rhythm Disruption in Cancer BiologyPharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disordersMass spectrometry-based secretome analysis of non-small cell lung cancer cell lines.PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patternsEpithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cellsAn integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer.3'UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network.Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progressionEmerging roles of PDGF-D signaling pathway in tumor development and progression.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Targeting the PDGF signaling pathway in tumor treatmentA novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancerMUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progressionDynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIMPlatelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progressionPTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancerCediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reactionA novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthGenome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profileDistinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cellsPlatelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cellsActivated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer.Autocrine PDGF stimulation in malignancies.Platelet-derived growth factors and their receptors: structural and functional perspectives.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.Down-regulation of platelet-derived growth factor-D expression blockades NF-κB pathway to inhibit cell proliferation and invasion as well as induce apoptosis in esophageal squamous cell carcinoma.PDGF-D/PDGF-ββ receptor-regulated chemotaxis of malignant mesothelioma cells.Inhibitory effect of soluble platelet-derived growth factor receptor β on intraosseous growth of breast cancer cells in nude mice.Curcumin facilitates fibrinolysis and cellular migration during wound healing by modulating urokinase plasminogen activator expression.The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth.
P2860
Q26859634-7902C5C9-FBAE-4CB9-9DD4-AC981E95367AQ27316378-B58E1221-0BEF-41BA-A620-3D3FD57FA35CQ28972554-A6FDDAA5-6AB4-4187-A581-03CF59CF1721Q29048615-8020D1CD-30BC-46F5-BFD6-933443F0FD16Q30313775-11607BD0-096D-4EE4-8BE7-CF4A79256C48Q30437153-16A9BB6F-C7E1-46B4-BE57-8F8552323403Q30988612-F9313BA4-B973-41FF-9F80-533119A3278CQ33325593-FC954DDE-13CC-49C4-BBA9-FE943F7B013CQ33788981-14D012B0-7E37-4122-B923-4A211F0577EDQ33866927-E4363AFC-DAED-4544-AB56-2EA7FEA86DB4Q33912608-6C284FB7-D251-44F0-ACBF-1A8474D50806Q34352802-144A1A5D-C1C7-4FBA-B393-03C024DE5E72Q34393461-BC084104-7AD1-415D-81AB-E5057F098E58Q34683885-ED652004-A5BC-467C-84BA-F9838F6BB831Q34737810-3F194E53-0827-4707-A8C9-53AD098732DCQ34988143-C649AD6D-0998-495F-9D4F-2AA53090B5F0Q34999819-2684EA1E-C720-4E86-9EB7-11D2BC48EB61Q35580879-81EAE517-785A-4A88-BB7A-28CCAF7413DDQ35839941-064E6CC4-7FF1-4D82-88E1-F396D23A2FA8Q35929823-29382D66-470D-4024-82FC-A20704FA843DQ35952035-7FE5F358-91BD-4280-AD9C-B66C1229D8AAQ36013452-F8B736AD-4C44-4075-8B7E-A4F4BFED94DBQ36352562-1A6EA8B5-7607-42BB-93FE-E1D36E886726Q36477174-877DED15-6BAC-4ECE-9AFC-D1972905FC0BQ36903863-B340D363-CD21-4668-B8B4-E708BF54450DQ37132900-F4520ACF-AC2A-47FF-A256-36D075857868Q37154190-B447419B-C338-40EF-BA2D-8FADE1F2818EQ37184447-87397DAB-9EC7-423C-99C9-C00455CCB42AQ37335608-863F0BC3-F412-40C4-8290-F8D76BB8634EQ37684112-0B43FF0A-E67F-42A4-8506-FF43E8ACED0AQ38003387-D5746873-9293-461D-8401-DDF96BD7BFCAQ38058615-F61813C5-6B36-4E37-B84A-A4C1F508EE5CQ38160946-BE1DADF4-1E29-4667-B102-426C0EB3CA5AQ38258904-73D42FEF-C483-4419-95B9-ED3F5B7E7A70Q38806364-BBD0066E-EFC5-433E-8D9C-B987CC157A83Q39237027-AB095D55-4455-4DB6-9410-CAAEA616F69BQ39380409-B986B752-66E2-411D-B51A-07859BB45455Q39511922-2D5D10C4-69EF-4601-A690-9307055E6DDFQ39632834-A98B36FF-CE8B-4276-B294-8F7B5E9410A6Q40181966-4BA6773E-544C-4F16-A29C-8CB61230E07E
P2860
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Platelet-derived growth factor ...... or in prostate carcinoma cells
@nl
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@ast
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en-gb
type
label
Platelet-derived growth factor ...... or in prostate carcinoma cells
@nl
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@ast
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en-gb
prefLabel
Platelet-derived growth factor ...... or in prostate carcinoma cells
@nl
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@ast
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en-gb
P2860
P3181
P1476
Platelet-derived growth factor ...... r in prostate carcinoma cells.
@en
P2093
Carolyn V Ustach
Hyeong-Reh Choi Kim
P2860
P304
P3181
P356
10.1128/MCB.25.14.6279-6288.2005
P407
P577
2005-07-01T00:00:00Z